References
- 1. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell. 100; 57-70.
- 2. Sotiriou C, Pusztai L. (2009). Gene-expression signatures in breast cancer. N Engl J Med. 360; 790-800.
- 3. Acharya A, Das I, Chandhok D, Saha T. (2010). Redox regulation in cancer: A double-edged sword with therapeutic potential. Oxid Med Cell Longev. 3; 23-34.
- 4. Milner JA. (2004). Molecular targets for bioactive food components. J Nutr. 134; 2492S-2498S.
- 5. Fenech M, Ferguson LR. (2001). Vitamins/minerals and genomic stability in humans. Mut Res. 475; 1-6.
- 6. Ivetic M, Velicki R, Popovic M, Cemerlic-Adjic N, Babovic SS, Velicki L. (2010). Dietary influence on breast cancer. Journal of BUON. 15(3); 455-461.
- 7. Siewit CL, Gengler B, Vegas E, Puckett R, Louie MC. (2010). Cadmium promotes breast cancer cell proliferation by potentiating the interaction between Er_ and c-Jun. Molecular Mol Endocrinol. 24(5); 981-992.
- 8. Gallagher CM, Chen JJ, Kovach JS. (2010). Enviromental cadmium and breast cancer risk. Aging. 2(11); 804-814.
- 9. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. (2006). Cadmium exposure and breast cancer risk. J Natl Cancer Inst. 98(12); 896-873.
- 10. Sandstead HH. (1994). Understanding zinc: recent observations and interpretations. J Lab Clin Med. 124(3); 322-327.
- 11. Heyneman CA. (1996). Zinc deficiency and taste disorders. Ann Pharmacother. 30(2); 186-187.
- 12. HoE, Ames BN. (2002). Low intracellular zinc induces oxidative DNA damage, disrupts p53, NFkappa B, and AP1 DNA binding, and affects DNA repair in a rat glioma cell line. Proc Natl Acad Sci U S A. 99(26); 16770-1675.
- 13. Fuwa K, Wacker WE, Druyan R, Bartholomay AF, Vallee BL. (1960). Nucleic Acids and Metals II: Transition Metals as Determinants of the Conformation of Ribonucleic Acids. Proc Natl Acad Sci USA. 46; 1298-1307.
- 14. Paski SC, Xu Z. (2001). Labile intracellular zinc is associated with 3T3 cell growth. J Nutr Biochem. 12; 655-661.
- 15. Andreini C, Banci L, Bertini I, Rosato A. (2006). Counting the zinc-proteins encoded in the human genome. J Proteome Res. 5; 196-201.
- 16. Sekler I, Sensi SL, Hershfinkel M, Silverman WF. (2007). Mechanism and regulation of cellular zinc transport. Mol Med. 13; 337-343.
- 17. Gaither LA, Eide DJ. (2001). Eukaryotic zinc transporters and their regulation. Biometals. 14; 251-270.
- 18. McClelland RA, Manning DL, Gee JM, Wishler P, Robertson JF, Ellis IO, Blamey RW, Nicholson RI. (1998). Oestrogen-regulated gene sin breast cancer: Association of pLIV1 with response to endocrine therapy. Br _ Cancer. 77; 1653-1656.
- 19. Vašák M, Hasler DW. (2000). Metallothioneins: new functional and structural insights. Curr Opin Chem Biol. 4(2); 177-183.
- 20. Andreini C, Banci L, Bertini I, Rosato A. (2006). Counting the zinc-proteins encoded in the human genome. J Proteome Res. 5(1); 196-201.
- 21. Liuzzi JP, Cousins RJ. (2004). Mammalian zinc transporters. Annu Rev Nutr. 24; 151-172.
- 22. DeWys W, Pories W. (1972). Inhibition of spectrum of animal tumors by dietary zinc deficiency. J Natl Cancer Inst. 48(2); 375-381.
- 23. McQuitty JT Jr, DeWys WD, Monaco L, Strain WH, Rob CG, Apgar J, Pories WJ. (1970). Inhibition of tumor growth by dietary zinc deficiency. Cancer Res. 30(5); 1387-1390.
- 24. Chakravarty PK, GhoshA, Chowdhury JR. (1976). Zinc in human malignances. Neoplasma. 33(1); 85-90.
- 25. Mulay IL, Roy R, Knox BE, Suhr NH, Delaney WE. (1971). Trace-metal analysis of cancerous and non cancerous human tissues. J Natl Cancer Inst. 47(1); 1-13.
- 26. Chasapis CT, Luotsidou AC, Spiliopoulou, Stefanidou ME. (2013). Zinc and human health: an update. Arch Toxicol. 86(4); 521-534.
- 27. Margalioth EJ, Schenker JG, Chevion M. 1983. Cooper and zinc levels in normal and malignant tissues. Cancer. 52(5); 866-872.
- 28. Alam S, Kelleher SL. (2012). Cellular mechanisms of zinc dysregulation: _ perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer. Nutritiens. 4(8); 875-903.
- 29. El-Tanani MK, Green CD. (1995). Oestrogen-induced genes, pLIV-1 and pS2, respond divergently to other steroid hormones in MCF-7 cells. Mol Cell Endocrinol. 111(1); 75-81.
- 30. Taylor KM, Morgan HE, Johnson A, Hadley LJ, Nicholson RI. (2003); Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem J. 375(Pt1); 51-59.
- 31. Kagara N, Tanaka N, Noguchi S, Hirano T. (2007). Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci. 98(5); 692-697.
- 32. Zhao L, Chen W, _aylor KM, Cai B, Li X. (2007). LIV-1 suppression inhibits HeLa cell invasion by targeting ERK/2-Snail/Slug pathway. Biochem Biophys Res Commun. 363(1); 82-88.
- 33. Kelleher SL, Seo YA, Lopez V. (2009). Mammary gland zinc metabolism: regulation and dysregulation. Genes Nutr. 4(2); 83-94.
- 34. Lichten LA, Cousins RJ. (2009). Mammalian zinc transporters: nutritional and physiologic regulation. Annu rev nutr. 29; 153-176.
- 35. McClelland RA, Manning DL, Gee JM, Willsher P, Robertson JF, Ellis IO, Blamey RW, Nicholson RI. (1998). Oestrogen-regulated genes in breast cancer: _ssociation of pLIV1 with response to endocrine therapy. Br J Cancer. 77(10); 1653-1656.
- 36. Manning DL, McClelland RA, Gee JM, Chan Cm, Green CD, Blamey RW, Nicholson RI. (1993). The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer. 29A(10); 1462-1468.
- 37. Taylor KM, Nicholson RI. (2003). The LZT proteins; the LIV-1 subfamily of zinc transporters. Biochim Biophysic Acta. 1611(1-2); 16-30.
- 38. Egeblad M, Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2(3); 161-174.
- 39. Lopez V, Foolad F, Kelleher SL. (2011). ZnT2-overexpression represses the cytotoxic effects of zinc hyperaccumulation in malignant metallothionein-null T47D breast tumor cells. Cancer Lett. 304(1); 41-51.
- 40. Truong-Tran AQ, Ho LH, Chai F, Zalewski PD. (2000). Cellular zinc fluxes and the regulation of apoptosis/genedirected cell death. J Nutr. 130(5S Suppl); 1459-1466.
- 41. Seo YA, Lopez V, Kelleher SL. (2011). A histidine-rich motif mediates mitochondrial localization of ZnT2 to modulate mitochondrial function. Am J Physiol Cell Physiol. 300(6); 1479-1489.
- 42. Prasad AS, Beck FW, Endre L, Handschu W, Kukuruga M, Kumar G. (1996). Zinc deficiency affects cell cycle and deoxythymidine kinase gene expression in HUT-78 cells. J Lab Clin Med. 128(1); 51-60.
- 43. Paski SC, Xu Z. (2002). Growth factor stimulated cell proliferation is accompanied by an elevated labile intracellular pool of zinc in 3T3 cells. Can J Physiol Pharmacol. 80(8); 790-795.
- 44. Franklin RB, Costello LC. (2009). The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem. 106(5); 750-757.
- 45. Provinciali M, Di Stefano G, Fabris N. (1995). Dosedependent opposite effect of zinc on apoptosis in mouse thymocytes. Int J Immunopharmacol. 17(9); 735-744.
- 46. Djekovic A, Petrovic B, Bugarcic ZD, Puchta R, van Eldik R. (2012). Kinetics and mechanism of the reactions of Au(III) complexes with some biologically relevant molecules. Dalton Trans. 41(13); 3633-3641.
- 47. Wang Y, He QY, Sun RW, Che CM, Chiu JF. (2005). GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 65(24); 11553-11564.
- 48. Lum CT, Liu X, Sun RW, Li XP, Peng Y, He ML, Kung HF, Che CM, Lin MC. (2010). Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro. Cancer Lett. 294(2); 159-166.
- 49. Jacques A, Lebrun C, Casini A, Kieffer I, Proux O, Latour JM, Sénèque O. (2015). Reactivity of Cys4 zinc finger domains with gold(III) complexes: insights into the formation of „gold fingers“. Inorg Chem. 54(8); 4104-4113.
- 50. Arsenijevic N. (2012). Biological Effects of Gold(III) Complexes Tested in Vitro and in Vivo. In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins ( pp. 933-935). New York, Heidelberg, Dordrecht, London:Springer.
- 51. Jain S, Coulter JA, Hounsell AR, Butterworth KT, Mc- Mahon SJ, Hyland WB, Muir MF, Dickson GR, Prise KM, Currell FJ, O’Sullivan JM, Hirst DG. (2011). Cell- Specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radial Oncol Biol Phys. 79(2); 531-539.
- 52. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. (2004). Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11(3); 169-183.
- 53. Huschka R, Zuloaga J, Knight MW, Brown LV, Nordlander P, Halas NJ. (2011). Light-induced release of DNA from gold nanoparticles: nanoshells and nanorods. J Am Chem. Soc. 133(31); 12247-12255.
- 54. Gibson JD, Khanal BP, Zubarev ER. (2007). Paclitaxelfunctionalized gold nanoparticles. J Am Chem Soc. 129(37); 11653-11661.
- 55. Liu H, Chen D, Li L, Liu T, Tan L, Wu X, Tang F. (2011). Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew Chem Int Ed Engl. 50(4); 891-895.
- 56. You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C. (2012). Photothermalchemotherapy with doxorubicin-loaded hollow gold nanospheres: _ platform for near-infrared light-trigged drug release. J Control Release. 158(2); 319-328.
- 57. Lee J, Chatterjee DK, Lee MH, Krishnan S. (2014). Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett. 347(1); 46-53.
- 58. Stuchinskaya T, Moreno M, Cook MJ, Edwards DR, Russell DA. (2011). Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyaninegold nanoparticle conjugates. Photochem Photobiol Sci. 10(5); 822-831.
- 59. Xu C, Wang B, Sun S. (2009). Dumbbell-like Au-Fe3O4 nanoparticles for target-specific platin delivery. J Am Chem Soc. 131(12); 4216-4217.
- 60. Joshi P, Chakraborti S, Ramirez-Vick JE, Ansari ZA, Shanker V, Chakrabarti P, Singh SP. (2012). The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells. Colloid Surf B Biointerfaces. 95; 195-200.